Drug reference
Lomitapide, an inhibitor of microsomal triglyceride transfer protein (MTP), reduces lipoprotein secretion and circulating concentrations of lipoprotein- borne lipids such as cholesterol and triglycerides.
PDF page 242
Adjunct to dietary measures and other lipid-regulating drugs with or without low-density lipoprotein apheresis in homozygous familial hypercholesterolaemia (under expert supervision) ▶BY MOUTH ▶Adult: Initially 5 mg daily for 2 weeks, dose to be taken at least 2 hours after evening meal, then increased if necessary to 10 mg daily, for at least 4 weeks, then increased to 20 mg daily for at least 4 weeks, then increased in steps of 20 mg daily, adjusted at intervals of at least 4 weeks; maximum 60 mg per day
PDF page 242
Significant or chronic bowel disease
PDF page 242
Concomitant use of hepatotoxic drugs. lomitapide can interfere with the absorption of fat-soluble nutrients and supplementation of vitamin E and fatty acids is required. patients over 65 years
PDF page 242
→Appendix 1: lomitapide
PDF page 242
▶Common or very common Aerophagia. appetite abnormal. asthenia. burping. constipation. diarrhoea. dizziness. gastrointestinal discomfort. gastrointestinal disorders. haemorrhage. headaches. hepatic disorders. increased risk of infection. muscle complaints. nausea. skin reactions. vomiting. weight decreased ▶Uncommon Anaemia. chest pain. chills. dehydration. drowsiness. dry mouth. eye swelling. fever. gait abnormal . hyperhidrosis. joint disorders. malaise. pain in extremity . paraesthesia. throat lesion. upper-airway cough syndrome. vertigo ▶Frequency not known Alopecia SIDE-EFFECTS, FURTHER INFORMATION Reduce dose if serum transaminases raised during treatment (consult product literature).
PDF page 242
Manufacturer advises exclude pregnancy before treatment and ensure effective contraception used.
PDF page 242
Avoid—teratogenicity and embryotoxicity in animal studies.
PDF page 242
Manufacturer advises avoid—no information available.
PDF page 242
Manufacturer advises avoid in moderate to severe impairment, or if unexplained persistent abnormal liver function tests. Dose adjustments Manufacturer advises max. 40 mg daily in mild impairment.
PDF page 242
Dose adjustments Max. 40 mg daily in end-stage renal disease.
PDF page 242
▶Monitor liver function tests before treatment, then at least monthly and before each dose increase for first year, then at least every 3 months and before each dose increase thereafter. ▶Screen for hepatic steatosis and fibrosis before treatment, then annually thereafter.
PDF page 242
There can be variation in the licensing of different medicines containing the same drug. Capsule ▶Lojuxta (Amryt Pharma) A Lomitapide 5 mg Lojuxta 5mg capsules | 28 capsule P £17,765.00 Lomitapide 10 mg Lojuxta 10mg capsules | 28 capsule P £17,765.00 Lomitapide 20 mg Lojuxta 20mg capsules | 28 capsule P £17,765.00
PDF pages 242, 243
Initially 5 mg daily for 2 weeks, dose to be taken
First-line fragment. Read the complete Indications and Dose section above.
PDF page 242
